- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
September 29th, 2006
Dendritic Nanotechnologies Inc. (DNT) and the National Cancer Institute (NCI) have entered into a Small Business Innovation Research (SBIR) contract valued at $850,000. The project will use DNT's Priostar(TM) dendrimers to develop a new generation of targeted diagnostic and therapeutic delivery technology for the early detection and treatment of epithelial ovarian cancer.
This marks the first time that dendrimer nanostructures will be used as both a diagnostic tool and a vehicle to deliver higher concentrations of therapeutic agents to cancerous cells.
|Related News Press|
Industrial Nanotech, Inc. Provides Shareholder Update August 22nd, 2016
Leading Advanced Materials Manufacturer Pixelligent Closes $10.4 Million in Funding: Capital Will Boost Capacity for North American Manufacturing, Drive Asian Expansion, and Continue Innovation in Solid State Lighting and OLED Display Applications August 16th, 2016
Harris & Harris Group to Host a Shareholder Update Call, Including a Presentation by One of Its Precision Health and Medicine Portfolio Companies, Muses Labs, Inc., on August 23, 2016 August 16th, 2016
50 years after the release of the film 'Fantastic Voyage,' science upstages fiction: Science upstages fiction with nanorobotic agents designed to travel in the human body to treat cancer August 25th, 2016
Graphene under pressure August 26th, 2016